<DOC>
	<DOCNO>NCT01857193</DOCNO>
	<brief_summary>Dose Escalation part study : To estimate MTD ( ) and/ RP2D LEE011 combination everolimus + exemestane , LEE011 combination exemestane , characterize safety tolerability combination everolimus + exemestane + LEE011 LEE011 + exemestane patient ER+ HER2- advance breast cancer Dose Expansion part study : To characterize safety tolerability triplet combination LEE011 + everolimus + exemestane patient naïve refractory CDK4/6 inhibitor base therapy , safety tolerability doublet combination LEE011 + exemestane patient refractory CDK4/6 inhibitor base therapy ( except patient treat prior LEE011 allow Group 3 ) .</brief_summary>
	<brief_title>Phase Ib Trial LEE011 With Everolimus ( RAD001 ) Exemestane Treatment Hormone Receptor Positive HER2 Negative Advanced Breast Cancer</brief_title>
	<detailed_description>The primary purpose phase Ib part study determine maximum tolerate dose ( ) ( MTD ( ) ) and/or recommend phase II dose ( RP2D ) LEE011 + everolimus + exemestane patient ER+ Her2- advance breast cancer . This part study also assess safety , tolerability , PK LEE011 + exemestane , LEE011 + everolimus + exemestane combination . The Dose Expansion part study evaluate triple combination LEE011 + everolimus + exemestane double combination LEE011 + exemestane safety tolerability .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Adult woman ( ≥ 18 year age ) metastatic locally advanced breast cancer Histological cytological confirmation ER+ and/or PR+ breast cancer A representative tumor specimen must available molecular testing . Postmenopausal woman . Postmenopausal status define either : Age ≥ 18 prior bilateral oophorectomy Age ≥ 60 year Age &lt; 60 year amenorrhea least 12 month folliclestimulating hormone ( FSH ) estradiol level postmenopausal range ( accord local laboratory ) Recurrence , within 12 month end adjuvant treatment letrozole anastrozole , Progression , within one month end letrozole anastrozole treatment locally advance metastatic breast cancer . Patients must : Measurable disease* : At least one lesion accurately measure least one dimension ≥ 20 mm conventional image technique ≥ 10 mm spiral CT MRI Bone lesion : lytic mixed ( lytic + sclerotic ) absence measurable disease define . ECOG Performance Status 01 . Fasting serum cholesterol ≤ 300 mg/dl 7.75 mmol/L fast triglyceride ≤ 2.5 × ULN . In case one threshold exceed , patient include initiation statin therapy mention value achieve Standard 12lead ECG value define mean triplicate ECGs assess central laboratory . QTcF interval screen &lt; 450 msec ( use Fridericia 's correction ) . Resting heart rate 5090 bpm HER2overexpressing patient local laboratory testing ( IHC 3+ stain situ hybridization positive ) . Patients receive one chemotherapy line advance breast cancer . Previous treatment exemestane mTOR inhibitors* ( Note : Patients disease refractory prior LEE011 exclude dose expansion Group 3 ) . History brain CNS metastasis . Clinically significant , uncontrolled heart disease and/or recent cardiac repolarization abnormality include follow : History myocardial infarction ( MI ) , angina pectoris , symptomatic pericarditis , coronary artery bypass graft ( CABG ) within 6 month prior study entry Documented cardiomyopathy Left ventricular ejection fraction ( LVEF ) &lt; 50 % determined Multiple Gated acquisition scan ( MUGA ) echocardiogram ( ECHO ) Long QT syndrome family history idiopathic sudden death congenital long QT syndrome , etc . Clinically significant cardiac arrhythmia , complete leave bundle branch block , highgrade AV block Systolic Blood Pressure ( SBP ) &gt; 160 &lt; 90 mmHg Patients currently receive treatment agent know cause QTc prolongation human ( Refer Appendix 3 ) Patients currently receive treatment ( within 7 day prior start study treatment ) strong moderate inhibitor inducer CYP3A4/5 , substrates CYP3A4/5 narrow therapeutic index Herbal preparations/medications ( Refer Section 6.4 Appendix 3 ) Inclusion Criteria Exceptions Phase Ib Dose Expansion patient : Dose Expansion part study 3 group , follow Inclusion Criteria exception 3 group 1 . Group 1 Patients must receive prior treatment CDK4/6 inhibitor 2 . Group 2 Patients must disease progression within one month CDK4/6 inhibitor base therapy 3 . Group 3 Patients must disease progression within one month CDK4/6 inhibitor base therapy ( except patient receive prior LEE011 base therapy ) . Other protocoldefined Inclusion/Exclusion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Open label ; dose escalation ; ER+ ; LEE011 ; CDK4/6 ; everolimus ; advanced breast cancer ; mTOR ; HR positive ; HER2 negative</keyword>
</DOC>